

PP45. Development of a pharmacoeconomics service in a provincial oncology centre

Malfair Taylor SC, Chow L

British Columbia Cancer Agency, Vancouver, BC, Canada

Background: The benefits of a pharmacoeconomics service include leading edge pharmacoeconomic research and evaluation for insight into formulary and drug benefit list considerations, and facilitation of enhanced incorporation of quality of life, cost effectiveness, and evidence based medicine into daily patient care. This means more cost-effective use of the drug budget and improved bargaining power for future budget considerations. Accordingly, a formal pharmacoeconomics service was designed and implemented.

Methods: A review of the pharmacoeconomic literature was completed.

Pharmacoeconomics and outcomes research conferences and symposia were attended. Data was synthesized to create a draft pharmacoeconomics proposal and template. This was informally circulated to establish interest in the service. Physicians preparing for clinical trials were approached to instill interest in adding a pharmacoeconomic component.

Results: The pharmacoeconomics service has an interdisciplinary team approach. This has been incorporated into the pharmacoeconomic analysis template. The template includes and describes how the pharmacist working on the service can coordinate and facilitate 1) meeting with key stakeholders to be involved with the pharmacoeconomic analysis to define objectives and initiate collaboration, 2) determining the desired perspective of the study such that the scope and the data requirements of the analysis can be defined, 3) determining the alternatives, 4) determining the outcomes, 5) selecting the appropriate method of pharmacoeconomic analysis, 6) determining monetary values, 7) identifying required resources, 8) establishing outcome probabilities, 9) incorporating decision analysis, 10) employing pharmacoeconomic manipulations: discounting, sensitivity analysis, and/or incremental cost analysis, and 11) presenting results.

Discussion: The first pharmacoeconomic study protocol to utilize the service commenced in May. The template was followed up to and including step 7. The pharmacoeconomics pharmacist has been named a co-principal investigator for the study. It is expected that the study will continue and the pharmacoeconomics pharmacist will follow the remaining steps of the template, facilitate, coordinate and complete the study. Results will be presented, submitted for publication, and used as part of a package to formally introduce the service widely throughout the entire provincial oncology agency.

Malfair Taylor SC, BC Cancer Agency, Pharmacy Department, 600 West 10th Ave., Vancouver, BC, V5Z 4A6, Canada

PP46. Economies of scale and technological efficiency in state-wide cancer detection programs

Mansley EC, May DS, Dunet DO

Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA

Background: In 1991 the Division of Cancer Prevention and Control (DCPC) at the Centers for Disease Control and Prevention (CDC) established the National Breast and Cervical Cancer Early Detection Program with the goal of increasing access to breast and cervical cancer screening services for women who are medically underserved. Since its inception, more than \$400 million has been awarded to fund comprehensive screening programs in all fifty states. As part of an effort to maximize the benefits derived from such an investment, DCPC has begun an economic investigation into the efficiency of the individual state programs.

Methods: Applying the theory of the firm to a screening program, we model the original eighteen state programs as productive processes and examine their average costs of production over a three to five-year period of operation. We consider alternative definitions of output, screening events and conditions detected. Output data is collected from the program's national database constructed from data provided by the states. Using information primarily from CDC's grants administration system, we estimate yearly program costs for each state from which both yearly and cumulative average costs are derived. Returns to scale and technological

efficiency are then explored utilizing the knowledge gained about the behavior of average costs.

Preliminary Results: Early analysis suggests significant economies of scale for screening programs that had no history of activity prior to federal funding. Cost per screen falls dramatically up to 75,000 screens and begins to stabilize thereafter. Cost per condition detected appears to behave in a similar fashion. Initial examination of yearly average costs for established programs reveals much less variation in yearly cost per screen relative to the variation in yearly cost per condition detected. Some programs appear to have unusually high average costs when compared to other states with similar cumulative output levels.

Discussion: Economies of scale in screening may indicate significant start-up costs incurred by a program early in its history. The corresponding drop in cumulative average cost as output expands suggests that the assumption of a constant cost per screen found in some cost-effectiveness analyses may be unfounded. Additionally, it suggests that premature evaluation of screening interventions may lead to faulty conclusions and suboptimal policy decisions. Unusually high average costs may indicate programs utilizing a relatively inefficient production technology. Such programs should be examined in more detail as they might benefit from restructuring.

Mansley EC, DCPC/NCCDPPH/CDC, 4770 Buford Hwy, NE, MS-K55, Atlanta, Georgia 30341-3724, USA

PP47. Efficiency of follow-up strategies after radical surgery for colonic cancer (RSCC). A decision analysis

Michel P^{1,2}, Merle V^{1,3}, Paillot B², Mauillon J^{1,2}, Duerotte P^{1,4}, Czernichow P^{1,3}

¹Groupe de Recherche sur l'Appareil Digestif, ²Centre de Dépistage et de Traitement des Tumeurs Digestives, ³Département d'Epidémiologie et de Santé Publique, ⁴Policlinique. Hôpital Charles Nicolle, Rouen Cedex, France

Background: The impact of follow-up after RSCC is uncertain and have never been tested in population study. Our aim was to compare the efficiency of 14 strategies after RSCC for Dukes B and C, with decision analysis method.

Method: Decision tree was made with the following data estimated from the literature: the population with colonic cancer is estimated to 20 500/y in France; The number of patients with colonic cancer Dukes B or C surviving after radical surgery is estimated to 10 500/y. After RSCC 45.4% are Dukes B and 54.6% Dukes C; The recurrence risk is estimated to 24% and 50% for Dukes B and C respectively, without adjuvant chemotherapy and 20% and 35% with adjuvant chemotherapy. A radical surgery of recurrence is possible in 30.7% and 17.7% of patients with and without follow-up respectively; in patients without recurrence the survival rate is 83%; in patients with recurrence it is 25% or 1.5% whether radical surgery is possible or not. We estimated the compliance of treatment and follow-up to 80% and 90% respectively. A sensitivity analysis tested all the parameters of the decision tree. The total cost and marginal cost were calculated in French Francs on the basis of French National Health's tariff 1996. The cost of adjuvant chemotherapy was calculated for 5Fluorouracile 370 mg/m² and Ac folinique 200 mg/m² protocol (D 1-D 1: 28d, 24 weeks). The cost of recurrence was not studied. The Olhsson follow-up protocol was used as standard (Dis Colon rectum 1995;38:619-626). The 14 strategies were presented in table 1 with survival rate at 5 years and cost of each strategies for 5 years.

Results: (Tt=Treatment, FU=Follow-Up, Du=Dukes)

| Table 1: | Survival % | Survival n | Cost 10 ⁶ FF | Marginal Cost/SO |
|---------------------------------|------------|------------|-------------------------|------------------|
| SO No Tt, No FU | 53.85 | 5654 | 0 | - |
| S1 No Tt, FU Du C with ACE+(C+) | 54.26 | 5698 | 20.4 | 0.47 |
| S2 No Tt, FU Du C | 54.53 | 5725 | 42.2 | 0.60 |
| S3 No Tt, FU Du B or C | 54.89 | 5763 | 99.2 | 0.91 |
| S4 Tt Du C, No FU | 58.07 | 6097 | 58.3 | 0.13 |
| S5 Tt Du C, FU Du C+<75ys | 58.28 | 6120 | 70.6 | 0.15 |
| S6 Tt Du C, FU Du C+ | 58.40 | 6132 | 78.8 | 0.16 |
| S7 Tt Du C, FU Du C<75ys | 58.40 | 6132 | 83.7 | 0.17 |
| S8 Tt Du C, FU Du C | 58.60 | 6153 | 100.6 | 0.20 |